Calendar

AAR has strong company-reported growth and FY2027 guidance, but the checked sources did not verify positive current-quarter estimate revisions or a revenue-upside signal, and the stock fell sharply into the event with weak close locations; operating momentum alone does not overcome the tape and evidence gaps.

AutoZone has credible upcoming EPS and revenue estimates, positive recent operating momentum, and a modest three-month revenue-estimate increase, but EPS estimates drifted lower and the stock sold off sharply into the event while XLY weakened; the tape does not support an upside-surprise setup.

Thor has a credible consensus EPS and revenue source and some resilient motorized and European demand, but both EPS and revenue estimates were revised lower, management cut full-year EPS guidance, the stock fell sharply into earnings, and XLY was weak; this is a cyclical turnaround watch rather than a pre-earnings surprise setup.

KB Home has a recent built-to-order catalyst, a positive five-session bounce, a strong close location, and above-normal volume, but accessible estimates imply sharply lower year-over-year EPS and revenue, estimate revisions were not available, housing-sector tape was weak, and the latest EPS miss keeps this below the surprise threshold.

Ferguson has solid recent operating execution and credible consensus EPS and revenue estimates, but the accessible sources did not verify positive estimate revisions or a whisper edge, while the stock was in a pronounced decline into earnings; the evidence is insufficient for a surprise-oriented setup.

The post-earnings narrative is improved and primarily supported by the company’s 8-K and earnings transcript, but coverage remains thin. The packet does not provide a verified analyst revision cycle or a separately measurable post-print price reaction; the latest anchor is $3.65 on 2026-08-17. Social data and options data are unavailable, so missing market confirmation should lower confidence rather than count as positive evidence.

The verified company 8-K is clearly positive on regulatory approval, clinical efficacy, NCCN positioning, and launch readiness. The post-earnings financial read-through is mixed because launch costs, cash burn, manufacturing-site approval, discounting, and uptake visibility remain unresolved. The packet provides no clean Aug. 13-Aug. 17 event-study or post-print analyst revision evidence; the available dated market-reaction item is a secondary July 15 report describing a double-digit decline after FDA approval, not an earnings-specific reaction. CELC's $92.44 Aug. 17 anchor confirms ongoing price caution but does not establish causality. [#SEC-8K-2026-08-13] [#PR-EARNINGS-2026-08-14]

The SEC-filed capital-allocation announcement closes the primary-source gap, but it does not provide operating results. No company-specific post-print price move, analyst revision, target change, or guidance reaction is available; the official August 27 schedule indicates that the queue appears stale or misaligned. Coverage remains sparse, peer comparability is improved only by adding IQ and 1024.HK, and missing reaction data is not treated as positive evidence.

The FY2026 filing provides a materially better backlog picture than the prior Q3 baseline, but the earnings-quality signal remains mixed because revenue, profit, and gross margin declined. No trusted post-print analyst revisions, consensus surprise data, or market-reaction attribution were available, and social coverage was absent. This remains a cautious monitoring setup rather than a high-conviction bullish thesis.

Headline tone is moderately positive because the company reported solid Q2 operating results and raised EBITDA guidance. The company source is confirmed through its Q2 results release and investor-relations materials. Third-party coverage reported post-print target increases from Baird and JPMorgan, while StockAnalysis showed ALH at $24.79 on August 17, down 2.67% from the prior close. The same date's selling-stockholder offering disclosure is a plausible overhang, but attribution of the price move to that announcement is not confirmed. Social and options data remain unavailable, and the lack of direct operating peers keeps this a cautious monitoring thesis.

News tone is mixed-positive: earnings and cash generation were solid, but margin compression and weaker digital-engagement indicators temper the thesis. The official IR analyst-coverage page provides current target and rating data, but not explicit post-print revisions. The deterministic anchor was $13.79 on August 17, 2026; a verified earnings-day price reaction was unavailable. Social, options, short-interest, and employee-sentiment data were not provided. The peer set lacks validated direct operating comparators, so this remains a low-conviction monitoring view.